Inventor · disambiguated record
Richard D. Woessner
Also filed as: WOESSNER RICHARD · WOESSNER RICHARD D · WOESSNER RICHARD DONALD
4 granted patents·6 pending applications·11 citations·filing 1999–2023
72Inventor score
Files withDIZAL JIANGSU PHARMACEUTICAL CO LTD3ARRAY BIOPHARMA INC2MEDIMMUNE INC1ONKURE INC1TUNQUIST BRIAN J1
Top patents by PatentIndex Score
10 records- 0186US11247983B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Feb 15, 2022·2 cites·19 claims
- 0286US10167276B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2017·Granted Jan 1, 2019·5 cites·5 claims
- 0384US10654835B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2018·Granted May 19, 2020·3 cites·22 claims
- 0468US9561214B2Method of treatment using inhibitors of mitosisTUNQUIST BRIAN J·Filed 2009·Granted Feb 7, 2017·1 cites·3 claims
- 0565US2009148459A1Prevention or Treatment of Cancer Using Integrin alphavbeta3 Antagonists in Combination with Other AgentsWOESSNER RICHARD·Filed 2008·Application pending·0 cites
- 0662US2025152560A1Hdac inhibitor oki-179 in combination with binimetinib for the treatment of cancerONKURE INC·Filed 2023·Application pending·0 cites
- 0756US2018338958A1Method of treatment using inhibitors of mitosisARRAY BIOPHARMA INC·Filed 2018·Application pending·0 cites
- 0852US2017172988A1Method of treatment using inhibitors of mitosisARRAY BIOPHARMA INC·Filed 2016·Application pending·0 cites
- 0947US2004001835A1Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agentsMEDIMMUNE INC·Filed 2003·Application pending·0 cites
- 1029US2001021772A1Short oligonucleotides for the inhibition of vegf expressionFiled 1999·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Richard D. Woessner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →